First-generation CBP inhibitors are limited by severe thrombocytopenia. TOLREMO's drug has shown no such toxicity in 45 patients, enabling a strategy to pursue the larger, more commercially attractive solid tumor market, rather than being confined to the initial validated indication of multiple myeloma.

Serenatus Bio is developing a novel COMT inhibitor based on Tolcapone, an old drug that showed efficacy in OCD but had severe liver toxicity. This strategy uses a flawed predecessor's clinical signal as proof-of-concept, de-risking the biological hypothesis while focusing innovation on solving the safety issues.

Terns' CML drug is an allosteric inhibitor, targeting a different site on the target protein than older drugs. This mechanism provides greater selectivity, avoiding off-target effects like arterial blockages common with active-site inhibitors. This technical advantage creates a compelling safety and tolerability profile, a key differentiator in a market with established therapies.

Instead of the traditional 'disease-target-drug' approach, Soleil finds compounds that create a desired cellular change first. Only after identifying a promising, well-tolerated molecule with a known cellular mechanism do they use bioinformatics to determine which disease and patient population it's best suited for.

Instead of targeting the final protein, Remix develops small molecules that intervene during pre-mRNA processing. This novel approach allows them to inhibit historically difficult drug targets like MYB, a transcription factor with no obvious binding sites, by preventing the disease-driving protein from ever being made.

The drug's mechanism is to block cancer's stress response. When a primary therapy like an EGFR inhibitor attacks a tumor, the cancer cells use CBP to reprogram and survive. By inhibiting CBP simultaneously, TOLREMO aims to prevent this escape, leading to deeper and more durable patient responses.

To target MYC, Dewpoint uses phenotypic screens that monitor the entire MYC condensate. This approach is mechanism-agnostic, capable of identifying compounds that work via previously attempted methods (e.g., disrupting binding) as well as novel ones like dissolving the condensate itself.

By focusing on the phenotypic outcome (cellular stress) rather than a predefined target, Soleil's platform can identify small molecules that modulate proteins considered undruggable by conventional means. Their lead oncology candidate, for example, modulates CCAP2, demonstrating the platform's ability to find novel biology and expand the druggable space.

Instead of screening vast libraries of compounds against a target, Hamlet first uses genome-wide and proteomic analysis to understand the core molecular basis of a disease. Only after defining the problem do they search for molecules to inhibit that specific disease pathway, letting the experiment guide them to the solution.